Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement

PLoS Neglected Tropical Diseases

Volumn 11, Issue 7, 2017, Pages

  Fink, Ashley L ^a,b   Williams, Katherine L ^c   Harris, Eva ^c   Alvine, Travis D ^a   Henderson, Thomas ^a   Schiltz, James ^d   Nilles, Matthew L ^a   Bradley, David S ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Avianax LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN Y; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; EPITOPE; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANSER (GENUS); ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 2; EGG YOLK; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; VACCINATION; ANIMAL; CELL LINE; CROSS REACTION; DENGUE VIRUS; GOOSE; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; SEVERE DENGUE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; CROSS REACTIONS; DENGUE VIRUS; EPITOPES; FEMALE; GEESE; HUMANS; IMMUNOGLOBULINS; MICE; MICE, KNOCKOUT; SEVERE DENGUE; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 85026785967     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005721     Document Type: Article

References (68)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. doi: 10.1038/nature12060 23563266;
2. WHODengue: guidelines for diagnosis, treatment, prevention and control: World Health Organization; 2009.
3. Gubler DJ, Dengue and dengue hemorrhagic fever. Clinical microbiology reviews. 1998;11(3):480–96. 9665979
4. Gubler DJ, Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century. Trop Med Health. 2011;39(4 Suppl):3–11. doi: 10.2149/tmh.2011-S05 22500131;
5. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS pathogens. 2010;6(4):e1000823. doi: 10.1371/journal.ppat.1000823 20369024
6. Gubler DJ, Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig Lecture. Am J Trop Med Hyg. 1989;40(6):571–8. 2472746.
7. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8(12 Suppl):S7–16. doi: 10.1038/nrmicro2460 21079655.
8. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg. 1997;56(5):566–72. 9180609.
9. Rodenhuis-Zybert IA, Wilschut J, Smit JM, Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci. 2010;67(16):2773–86. doi: 10.1007/s00018-010-0357-z 20372965.
10. Kalayanarooj S, Nimmannitya S, Clinical presentations of dengue hemorrhagic fever in infants compared to children. J Med Assoc Thai. 2003;86Suppl 3:S673–80. 14700166.
11. Whitehorn J, Yacoub S, Anders KL, Macareo LR, Cassetti MC, Nguyen Van VC, et al. Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions. PLoS Negl Trop Dis. 2014;8(8):e3025. doi: 10.1371/journal.pntd.0003025 25166493;
12. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS pathogens. 2010;6(2):e1000790. doi: 10.1371/journal.ppat.1000790 20168989
13. Faith RE, Clem LW, Passive cutaneous anaphylaxis in the chicken. Biological fractionation of the mediating antibody population. Immunology. 1973;25(1):151–64. 4737364;
14. Warr GW, Magor KE, Higgins DA, IgY: clues to the origins of modern antibodies. Immunology today. 1995;16(8):392–8. doi: 10.1016/0167-5699(95)80008-5 7546196
15. Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, et al. Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. PLoS Negl Trop Dis. 2015;9(6):e0003803. doi: 10.1371/journal.pntd.0003803 26046641;
16. Kovacs-Nolan J, Mine Y, Avian egg antibodies: basic and potential applications. Avian and Poultry Biology Reviews. 2004;15(1):25–46.
17. Spillner E, Braren I, Greunke K, Seismann H, Blank S, du Plessis D, Avian IgY antibodies and their recombinant equivalents in research, diagnostics and therapy. Biologicals. 2012.
18. Woof JM, Burton DR, Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4(2):89–99. doi: 10.1038/nri1266 15040582.
19. Carlander D, Stålberg J, Larsson A, Chicken antibodies: a clinical chemistry perspective. Upsala journal of medical sciences. 1999;104(3):179–89. 10680951
20. Kronval G, Seal US, Svensson S, Williams RC, Phylogenetic aspects of staphylococcal protein A-reactive serum globulins in birds and mammals. Acta Pathologica Microbiologica Scandinavica Section B Microbiology and Immunology. 1974;82(1):12–8.
21. Larsson A, Sjöquist J, Binding of complement components C1q, C3, C4 and C5 to a model immune complex in ELISA. J Immunol Methods. 1989;119(1):103–9. 2785142.
22. Larsson A, Sjöquist J, Chicken IgY: utilizing the evolutionary difference. Comp Immunol Microbiol Infect Dis. 1990;13(4):199–201. 2076606.
23. Larsson A, Wejåker PE, Forsberg PO, Lindahl T, Chicken antibodies: a tool to avoid interference by complement activation in ELISA. J Immunol Methods. 1992;156(1):79–83. 1431165.
24. Larsson A, Bålöw RM, Lindahl TL, Forsberg PO, Chicken antibodies: taking advantage of evolution—a review. Poult Sci. 1993;72(10):1807–12. 8415358.
25. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, et al. Vascular Leakage in Severe Dengue Virus Infections: A Potential Role for the Nonstructural Viral Protein NS1 and Complement. The Journal of Infectious Diseases. 2006;193(8):1078–88. doi: 10.1086/500949 16544248
26. Marinho CF, Azeredo EL, Torrentes-Carvalho A, Marins-Dos-Santos A, Kubelka CF, de Souza LJ, et al. Down-regulation of complement receptors on the surface of host monocyte even as in vitro complement pathway blocking interferes in dengue infection. PLoS One. 2014;9(7):e102014. doi: 10.1371/journal.pone.0102014 25061945;
27. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, et al. Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus. Cell Host & Microbe. 2009;6(4):381–91. doi: 10.1016/j.chom.2009.09.003 19837377.
28. Navarro-Sánchez E, Desprès P, Cedillo-Barrón L, Innate immune responses to dengue virus. Arch Med Res. 2005;36(5):425–35. doi: 10.1016/j.arcmed.2005.04.007 16099317.
29. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E, Murine model for dengue virus-induced lethal disease with increased vascular permeability. Journal of virology. 2006;80(20):10208–17. doi: 10.1128/JVI.00062-06 17005698
30. Williams KL, Wahala WMPB, Orozco S, de Silva AM, Harris E, Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 2012;429(1):12–20. doi: 10.1016/j.virol.2012.03.003 22537810;
31. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, et al. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog. 2013;9(2):e1003157. doi: 10.1371/journal.ppat.1003157 23459315;
32. Brien JD, Sukupolvi-Petty S, Williams KL, Lam CY, Schmid MA, Johnson S, et al. Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol. 2013;87(13):7747–53. doi: 10.1128/JVI.00327-13 23658441;
33. Crill WD, Chang G-JJ, Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78(24):13975–86. doi: 10.1128/JVI.78.24.13975-13986.2004 15564505;
34. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WMPB, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109(19):7439–44. doi: 10.1073/pnas.1200566109 22499787;
35. Falconar AK, Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol. 1999;144(12):2313–30. 10664386.
36. Falconar AKI, Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. Clin Vaccine Immunol. 2007;14(5):493–504. doi: 10.1128/CVI.00371-06 17329445;
37. Falconar AKI, Use of synthetic peptides to represent surface-exposed epitopes defined by neutralizing dengue complex- and flavivirus group-reactive monoclonal antibodies on the native dengue type-2 virus envelope glycoprotein. J Gen Virol. 2008;89(Pt 7):1616–21. doi: 10.1099/vir.0.83648-0 18559931.
38. Gromowski GD, Barrett ADT, Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007;366(2):349–60. doi: 10.1016/j.virol.2007.05.042 17719070.
39. Gromowski GD, Barrett ND, Barrett ADT, Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008;82(17):8828–37. doi: 10.1128/JVI.00606-08 18562544;
40. Huang JH, Wey JJ, Sun YC, Chin C, Chien LJ, Wu YC, Antibody responses to an immunodominant nonstructural 1 synthetic peptide in patients with dengue fever and dengue hemorrhagic fever. J Med Virol. 1999;57(1):1–8. 9890415.
41. Jiang L, Zhou J-M, Yin Y, Fang D-Y, Tang Y-X, Jiang L-F, Selection and identification of B-cell epitope on NS1 protein of dengue virus type 2. Virus Res. 2010;150(1–2):49–55. doi: 10.1016/j.virusres.2010.02.012 20211209.
42. Li P-C, Liao M-Y, Cheng P-C, Liang J-J, Liu I-J, Chiu C-Y, et al. Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis. 2012;6(5):e1636. doi: 10.1371/journal.pntd.0001636 22563515;
43. Lin H-E, Tsai W-Y, Liu I-J, Li P-C, Liao M-Y, Tsai J-J, et al. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis. 2012;6(1):e1447. doi: 10.1371/journal.pntd.0001447 22235356;
44. Lisova O, Hardy F, Petit V, Bedouelle H, Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol. 2007;88(Pt 9):2387–97. doi: 10.1099/vir.0.83028-0 17698647.
45. Liu I-J, Chiu C-Y, Chen Y-C, Wu H-C, Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem. 2011;286(11):9726–36. doi: 10.1074/jbc.M110.170993 21233208;
46. Masrinoul P, Diata MO, Pambudi S, Limkittikul K, Ikuta K, Kurosu T, Highly conserved region 141–168 of the NS1 protein is a new common epitope region of dengue virus. Jpn J Infect Dis. 2011;64(2):109–15. 21519123.
47. Moreland NJ, Tay MYF, Lim E, Paradkar PN, Doan DNP, Yau YH, et al. High Affinity Human Antibody Fragments to Dengue Virus Non-Structural Protein 3. PLoS Negl Trop Dis. 2010;4(11):e881. doi: 10.1371/journal.pntd.0000881 21085466
48. Steidel M, Fragnoud R, Guillotte M, Roesch C, Michel S, Meunier T, et al. Nonstructural protein NS1 immunodominant epitope detected specifically in dengue virus infected material by a SELDI-TOF/MS based assay. J Med Virol. 2012;84(3):490–9. doi: 10.1002/jmv.23204 22246837.
49. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010;84(18):9227–39. doi: 10.1128/JVI.01087-10 20592088;
50. Tian Y, Chen W, Yang Y, Xu X, Zhang J, Wang J, et al. Identification of B cell epitopes of dengue virus 2 NS3 protein by monoclonal antibody. Appl Microbiol Biotechnol. 2013;97(4):1553–60. doi: 10.1007/s00253-012-4419-z 23081772.
51. Cheng H-J, Lei H-Y, Lin C-F, Luo Y-H, Wan S-W, Liu H-S, et al. Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol Immunol. 2009;47(2–3):398–406. doi: 10.1016/j.molimm.2009.08.033 19822367.
52. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NTH, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8(3):271–83. doi: 10.1016/j.chom.2010.08.007 20833378;
53. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science Signaling. 2010;328(5979):745.
54. Alvarez-Rodriguez LM, Ramos-Ligonio A, Rosales-Encina JL, Martinez-Cazares MT, Parissi-Crivelli A, Lopez-Monteon A, Expression, purification, and evaluation of diagnostic potential and immunogenicity of a recombinant NS3 protein from all serotypes of dengue virus. J Trop Med. 2012;2012:956875. doi: 10.1155/2012/956875 23258983;
55. Rau H, Revets H, Balmelli C, McCullough KC, Summerfield A, Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res. 2006;37(1):155–68. doi: 10.1051/vetres:2005049 16336932.
56. Valdés K, Alvarez M, Pupo M, Vázquez S, Rodríguez R, Guzmán MG, Human dengue antibodies against structural and nonstructural proteins. Clinical and diagnostic laboratory immunology. 2000;7(5):856–7. 10973471
57. Moraes AH, Simonelli L, Pedotti M, Almeida FC, Varani L, Valente AP, Antibody Binding Modulates Conformational Exchange in Domain III of Dengue Virus E Protein. J Virol. 2015;90(4):1802–11. doi: 10.1128/JVI.02314-15 26637461;
58. Kollberg H, Carlander D, Olesen H, Wejåker P-E, Johannesson M, Larsson A, Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatric pulmonology. 2003;35(6):433–40. doi: 10.1002/ppul.10290 12746939
59. Nilsson E, Kollberg H, Johannesson M, Wejåker P-E, Carlander D, Larsson A, More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. Journal of medicinal food. 2007;10(2):375–8. doi: 10.1089/jmf.2006.214 17651078
60. Nilsson E, Larsson A, Olesen HV, Wejåker P-E, Kollberg H, Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatric pulmonology. 2008;43(9):892–9. doi: 10.1002/ppul.20875 18680179
61. Ibrahim el SM, Rahman AK, Isoda R, Umeda K, Van Sa N, Kodama Y, In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY). Vaccine. 2008;26(17):2073–80. doi: 10.1016/j.vaccine.2008.02.046 18375022.
62. Wang XZ, Fan B, Liu LG, Hu XY, Li RY, Wei Y, et al. In vitro inhibition of oral Candida albicans by chicken egg yolk antibody (IgY). Mycopathologia. 2008;165(6):381–7. doi: 10.1007/s11046-008-9097-0 18340547.
63. Almeida CM, Kanashiro MM, Rangel Filho FB, Mata MF, Kipnis TL, da Silva WD, Development of snake antivenom antibodies in chickens and their purification from yolk. Vet Rec. 1998;143(21):579–84. 9854769.
64. Meenatchisundaram S, Parameswari G, Michael A, Ramalingam S, Studies on pharmacological effects of Russell's viper and Saw-scaled viper venom and its neutralization by chicken egg yolk antibodies. Int Immunopharmacol. 2008;8(8):1067–73. doi: 10.1016/j.intimp.2008.03.017 18550009.
65. Meenatchisundaram S, Parameswari G, Michael A, Ramalingam S, Neutralization of the pharmacological effects of Cobra and Krait venoms by chicken egg yolk antibodies. Toxicon. 2008;52(2):221–7. doi: 10.1016/j.toxicon.2008.04.179 18590753.
66. Akita EM, Jang CB, Kitts DD, Nakai S, Evaluation of allergenicity of egg yolk immunoglobulin Y and other egg proteins by passive cutaneous anaphylaxis. Food Agr Immunol. 1999;11(2):191–201.
67. Torche AM, Le Dimna M, Le Corre P, Mesplede A, Le Gal S, Cariolet R, et al. Immune responses after local administration of IgY loaded-PLGA microspheres in gut-associated lymphoid tissue in pigs. Veterinary Immunology and Immunopathology. 2006;109(3–4):209–17. doi: 10.1016/j.vetimm.2005.08.016 16219363
68. Vega CG, Bok M, Vlasova AN, Chattha KS, Fernández FM, Wigdorovitz A, et al. IgY antibodies protect against human Rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model. PloS one. 2012;7(8):e42788. doi: 10.1371/journal.pone.0042788 22880110